RA Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

RA Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-70,613	Closed	-$6.72M	–	32
2018 Q1	$6.72M	Sell	70,613 -17,868	-20%	-$3.06M	0.52%	25
2017 Q4	$11.4M	Buy	+88,481	New	+$8.29M	0.96%	20
2014 Q4	–	Sell	-23,187	Closed	-$34.8M	–	56
2014 Q3	$34.8M	Hold	23,187	–	–	4.11%	7
2014 Q2	$31.7M	Hold	23,187	–	–	3.21%	10
2014 Q1	$32.2M	Hold	23,187	–	–	2.31%	16
2013 Q4	$23.1M	Hold	23,187	–	–	2.69%	13
2013 Q3	$24.2M	Buy	23,187 +728	+3%	+$778K	2.52%	15
2013 Q2	$24.5M	Buy	+22,459	New	+$25M	3.24%	12

Other funds holding VIRX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

RA Capital Management's VIRX Position: Q2 2018 in Review

RA Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2018, closing a stake of 70,613 shares — an estimated $6.72M sold.

RA Capital Management first reported a position in VIRX in Q2 2013 and held it in 8 quarters. The position peaked at $34.8M in Q3 2014. 50 funds tracked by Wall St. Rank hold VIRX as of Q2 2018.

RA Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
RA Capital Management sold 70,613 Viracta Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $6.72M.
RA Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
RA Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $34.8M in Q3 2014.
50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on RA Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.